Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab plus Chidamide in R/R Angioimmunoblastic T-cell Lymphoma
NCT04831710Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Apr 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in angioimmunoblastic T-cell lymphoma (AITL), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
sintilimab
03
Conditions
angioimmunoblastic T-cell lymphoma (AITL)
Beyond the preview
Go deeper on NCT04831710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04831710.